Method of using FOXO3A polymorphisms and haplotypes to predict and promote healthy aging and longevity
AssigneeKuakini Medical Center
InventorsTimothy Atchison Donlon, Bradley John Wilcox, J. David Curb
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions relating to identification and use of genetic information from the FOXO3A gene that can be used for determining and increasing an individual's likelihood of longevity and of retaining physical and cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease, including coronary artery (heart) disease, stroke, cancer, chronic pulmonary disease, diabetes, Parkinson's disease and dementia.
Claims10
A method of monitoring FOXO3A GCC allele expression, the method comprising:
- a) obtaining a pre-administration cell sample from a subject prior to administration of a therapeutic agent;
- b) detecting the level of FOXO3A GCC allele expression in the pre-administration sample;
- c) obtaining at least one post-administration sample from the subject;
- and
- d) detecting the level of FOXO3A GCC allele expression in the at least one post-administration sample,
- wherein detecting the level of FOXO3A allele expression in the samples comprises:
- detecting at least one “G” allele of the locus/polymorphism rs2802292 in the FOXO3A gene at the position corresponding to position 467 of SEQ ID NO:
- 4;
- detecting at least one “C” allele of the locus/polymorphism rs13217795 in the FOXO3A gene at the position corresponding to position 301 of SEQ ID NO:
- 3;
- detecting at least one “C” allele of the locus/polymorphism rs2764264 in the FOXO3A gene at the position corresponding to position 501 of SEQ ID NO:
- 2;
- wherein the “G” allele of rs2802292, the “C” allele of rs13217795, and the “C” allele of rs276424 constitute a GCC haplotype of a FOXO3 A gene, and expression from the FOXO3 A gene comprising the GCC haplotype is detected.
A method of monitoring FOXO3A GCC allele expression, the method comprising:
- a) obtaining a pre-administration cell sample from a subject prior to administration of a therapeutic agent;
- b) detecting the level of FOXO3A GCC allele expression in the pre-administration sample;
- c) obtaining at least one post-administration sample from the subject;
- and
- d) detecting the level of FOXO3A GCC allele expression in the at least one post-administration sample, wherein detecting the level of FOXO3A allele expression in the samples comprises:
- detecting at least one “G” allele of the locus/polymorphism rs2802292 in the FOXO3A gene at the position corresponding to position 467 of SEQ ID NO:
- 4;
- detecting at least one “C” allele of the locus/polymorphism rs13217795 in the FOXO3A gene at the position corresponding to position 301 of SEQ ID NO:
- 3;
- detecting at least one “C” allele of the locus/polymorphism rs2764264 in the FOXO3A gene at the position corresponding to position 501 of SEQ ID NO:
- 2;
- wherein the “G” allele of rs2802292, the “C” allele of rs13217795, and the “C” allele of rs276424 constitute a GCC haplotype of a FOXO3A gene, and expression from the FOXO3A gene comprising the GCC haplotype is detected;
- and
- furthermore wherein a nucleic acid assay is used to detect the level of FOXO3A GCC allele and wherein the nucleic acid assay uses at least one synthetic primer.
Dependencies are inferred from the claim text.